ClinicalTrials.gg
CompletedNCT02864706CRAD001ANO05Updated Oct 3, 2019Results posted

SCHEDULE Follow Up Visit 5-7 yr

A Phase 4 interventional study of Everolimus and Cyclosporine in Heart Transplantation, sponsored by Novartis Pharmaceuticals. Completed at 6 sites in 3 countries. Per ClinicalTrials.gov, last updated 2019-10-03.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Jan 2016, registered Jun 2016).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
95
Allocation
Non-randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies in Graft vs Host Disease by Novartis — 2 open to participants now, 4 under way, none of them phase 3. Graft vs Host Disease · Novartis.

Enrollment
5th of 10
95 · median 84
Started
2016
the only one that year
Phase 4
5 of 12
1 open now
Registered
5th of 12
by date

Among the 12 studies in Graft vs Host Disease by Novartis, this one is the 5th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2016, is one of 5 in phase 4, and was the 5th registered.

Graft vs Host Disease

804 studies on the registry are indexed under Graft vs Host Disease; 149 are open to participants now.

Browse Graft vs Host Disease studies →

Open to participants now

2 of the 12 studies in Graft vs Host Disease by Novartis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 103 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 42 (41%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Graft vs Host Disease by Novartis, or all of them as a file.
02

Study summary

The major aim of this extension study was to evaluate the long-term effect (i.e. 5 to 7 years) of early initiation of everolimus and early elimination of CsA compared to standard immunosuppressive regimen including CsA on primary and secondary endpoints investigated in the SCHEDULE (NCT01266148) main study.

Read the detailed description

This protocol was written to describe the procedures for a single 5, 6 or 7 year follow-up control visit of patients who participated in the 12-month SCHEDULE (NCT01266148) study and the following 3-year follow-up examination/visit. The aim of this 5 to 7-year follow-up visit was to examine the effect of long term treatment, i.e. 5, 6 or 7 years, with early initiation of everolimus (Certican®) and early elimination of cyclosporine (CsA), compared to standard immunosuppressive regimen including CsA, on renal and heart function. During the time period of this follow-up examinations, this visit was performed as part of a routine annual visit 5, 6 or 7 years since transplantation (and inclusion in the original SCHEDULE study).

Study code of SCHEDULE, the core study: CRAD001ANO02 (EudraCT No.: 2009-013074-41)

03

Conditions studied

  • Heart Transplantation

Browse trials for

Keywords

  • allograft rejection
  • xenograft rejection
  • host vs graft disease
  • transplant
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who participated in the SCHEDULE 12-month main study, and who completed the 3 year follow-up visit
  • Patients who are coming for a regular annual clinic visit 5 to 7 years after randomization in the main study
  • Obtaining of a separate signed patient will be required for participation in this follow-up examination.

Exclusion criteria

Exclusion Criteria:

  • Patients with a retransplanted heart since the original SCHEDULE study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
95 participants (actual)

Study arms

  • Experimental
    EVEROLIMUS

    patients received everolimus (Certican), low-exposure CsA (Neoral), mycophenolate mofetil (MMF) and corticosteroids with CsA withdrawal after 7-11 weeks

    Drug: Everolimus

  • Active comparator
    Control

    patients received standard CsA, MMF and corticosteroids

    Drug: Cyclosporine · Drug: Mycophenolate mofetil · Drug: Corticosteroids

Interventions

  • All patients, independent of their initial randomization in the core study, were followed up as in one single group Commercially available everolimus (Certican®), oral route, was used.

  • Cyclosporine (CsA) control group target blood level: 150-350 ng/mL (month 1-3); 100-250 ng/mL (month 4-6); 60-200 ng/mL (month 7-12); everolimus group target blood level: 75-175 ng/mL (month 1-3)

  • Mycophenolate mofetil (MMF) target dose for control group: 2000-3000 mg/day everolimus group target dose: 1500-2000 mg/day and 75-175 ng/mL after week 11

  • DrugCorticosteroids

    Corticosteroids (CS) initiated at 0.2-0.5 mg/kg/day. Tapered to no less than 0.1 mg/kg at Month 3 for control and everolimus groups.

06

What researchers measure

Primary outcomes

  1. Measured Glomerular Filtration Rate (mGFR)

    Renal function as assessed by measured Glomerular Filtration Rate (mGFR) (Cr-EDTA or iohexol clearance). Baseline Visit 1 and Patient 4252 excluded from the intent treat analysis set.

    Time frame: at the 5-7 year follow-up visit

Secondary outcomes

  1. Progression of Cardiac Allograft Vasculopathy (CAV) Recorded by Intravascular Ultrasound (IVUS)

    Cardiac Allograft Vasculopathy (CAV) was defined as mean maximal intimal thickness (MIT) ≥0.5 mm, measured for the entire matched pullback recording by intravascular ultrasound (IVUS). The incidence of CAV at 5-7 years was compared between groups using the Cochran-Mantel-Haenszel test with stratification according to baseline distribution of CAV incidence.

    Time frame: within 5-7 years

  2. Percent of Participants With Incidence of Coronary Allograft Vasculopathy (CAV)

    Cardiac Allograft Vasculopathy (CAV) was defined as mean maximal intimal thickness (MIT) ≥0.5 mm, measured for the entire matched pullback recording by intravascular ultrasound (IVUS). The incidence of CAV at 5-7 years was compared between groups using the Cochran-Mantel-Haenszel test with stratification according to baseline distribution of CAV incidence.

    Time frame: at the 5-7 year follow-up

  3. Myocardial Structure and Function

    Myocardial structure and function by echocardiography assessment measured by ventricular end systolic diameter.

    Time frame: within 5-7 years

  4. Quality of Life by SF-36 Change From Pre-transplantation to 5-7 Year Follow-up

    This Quality of life Short Form Survey with 36 items (Minnesota Living with Heart Failure Questionnaire)was administered to patients pre-transplantation and after transplantation at the 5-7 year visit. This data represents the change. The survey consist of scores on a scale. Each form is scaled from 0 t 100. 0 = maximum disability and 100 equals no disability.

    Time frame: at the 5-7 year visit

  5. Change From Baseline in the Euro Quality of Life 5D

    Change from baseline in Euro Quality of Life-5D from 3 Year Follow-Up to 5 to 7 Year Follow-Up Baseline Visit 1 (ITT Set) Euro Quality of Life 5D (EQ-5D): is a descriptive system of healthrelated quality of life states consisting of five dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) each of which can be assessed as one of three levels of severity (no problems/some or moderate problems/extreme problems). A Visual Analogue Scale (VAS)-scale is also included in the EQ-5D questionnaire. The EQ-5D index is calculated based on the United Kingdom Time Trade-Off (TTO) N3 value set which converts the five dimensions scores into a single measure with a possible range from -0.163 (worst possible health state) to +1 (perfect health). A positive change from baseline indicates an improvement in Quality of Life.

    Time frame: Baseline, 5-7 year visit

  6. Change From Baseline in Visual Analog Scale (VAS)

    Change in visual analog scale (VAS) from baseline to the 5 to 7 Year follow up visit. 0 is no pain; and 10 is the worst possible pain

    Time frame: baseline, at the 5-7 year visit

  7. Number of Participants With Beck Depression Inventory (BDI)

    Beck Depression Inventory (BDI) Score has the following categories of depression. Normal, Mild, Moderate Severe and Missing.

    Time frame: at the 5-7 year visit

07

Results

Posted Oct 3, 2019
Limitations and caveats
There is no investigational medicinal product (IMP). This study is a single follow-up visit. Hence patients' first and last visit dates are the same.

Participant flow

In total, 95 patients (48 everolimus, 47 controls), attended the follow-up visit at 5-7 years post-transplant and were included in the safety population The PP population (27 everolimus, 35 controls) excluded 7 patients in the everolimus group and 11 in the control group who discontinued study drug prematurely

Participant flow — Overall Study
MilestoneEverolimusControl
Started4847
Safety set4847
Intent to treat4647
Completed4847
Not completed00

Outcome measures

PrimaryMeasured Glomerular Filtration Rate (mGFR)

Renal function as assessed by measured Glomerular Filtration Rate (mGFR) (Cr-EDTA or iohexol clearance). Baseline Visit 1 and Patient 4252 excluded from the intent treat analysis set.

Time frame:
at the 5-7 year follow-up visit
Reported as:
Least squares mean · mL/min/1.73m2
Measured Glomerular Filtration Rate (mGFR)
mL/min/1.73m2EverolimusControl
Measured Glomerular Filtration Rate (mGFR)74.7 ± 23.362.4 ± 16.5
Statistical analysis
  • Everolimus vs Control · ANCOVA · p = 0.0043Incidence of CAV at 5-7 yrs was compared between groups using Cochran-Mantel-Haenszel test with stratification according to baseline distribution
SecondaryProgression of Cardiac Allograft Vasculopathy (CAV) Recorded by Intravascular Ultrasound (IVUS)

Cardiac Allograft Vasculopathy (CAV) was defined as mean maximal intimal thickness (MIT) ≥0.5 mm, measured for the entire matched pullback recording by intravascular ultrasound (IVUS). The incidence of CAV at 5-7 years was compared between groups using the Cochran-Mantel-Haenszel test with stratification according to baseline distribution of CAV incidence.

Time frame:
within 5-7 years
Reported as:
Mean · mm
Progression of Cardiac Allograft Vasculopathy (CAV) Recorded by Intravascular Ultrasound (IVUS)
mmEverolimusControl
Progression of Cardiac Allograft Vasculopathy (CAV) Recorded by Intravascular Ultrasound (IVUS)0.13 ± 0.150.23 ± 0.24
Statistical analysis
  • Everolimus vs Control · Cochran-Mantel-Haenszel · p = 0.037
SecondaryPercent of Participants With Incidence of Coronary Allograft Vasculopathy (CAV)

Cardiac Allograft Vasculopathy (CAV) was defined as mean maximal intimal thickness (MIT) ≥0.5 mm, measured for the entire matched pullback recording by intravascular ultrasound (IVUS). The incidence of CAV at 5-7 years was compared between groups using the Cochran-Mantel-Haenszel test with stratification according to baseline distribution of CAV incidence.

Time frame:
at the 5-7 year follow-up
Reported as:
Number · percent of participants
Percent of Participants With Incidence of Coronary Allograft Vasculopathy (CAV)
percent of participantsEverolimusControl
Percent of Participants With Incidence of Coronary Allograft Vasculopathy (CAV)5374
SecondaryMyocardial Structure and Function

Myocardial structure and function by echocardiography assessment measured by ventricular end systolic diameter.

Time frame:
within 5-7 years
Reported as:
Mean · cm
Myocardial Structure and Function
cmEverolimusControl
LVESD (left ventricular end systolic diameter)3.1 ± 0.83.1 ± 0.6
LVEDD (left ventricular end diastolic diameter)4.7 ± 0.64.9 ± 0.6
SecondaryQuality of Life by SF-36 Change From Pre-transplantation to 5-7 Year Follow-up

This Quality of life Short Form Survey with 36 items (Minnesota Living with Heart Failure Questionnaire)was administered to patients pre-transplantation and after transplantation at the 5-7 year visit. This data represents the change. The survey consist of scores on a scale. Each form is scaled from 0 t 100. 0 = maximum disability and 100 equals no disability.

Time frame:
at the 5-7 year visit
Reported as:
Mean · scores on a scale
Quality of Life by SF-36 Change From Pre-transplantation to 5-7 Year Follow-up
scores on a scaleEverolimusControl
Physical Health Summary16.8 ± 15.013.2 ± 13.3
Mental Health Summary10.4 ± 10.515.3 ± 15.5
Physical Functioning36.7 ± 38.440.8 ± 30.4
Role Physical50.2 ± 32.355.1 ± 32.4
Bodily Pain10.3 ± 34.87.2 ± 34.1
General Health25.7 ± 26.423.4 ± 25.6
Vitality30.0 ± 25.828.9 ± 29.0
Social Functioning39.9 ± 31.543.9 ± 32.4
Role Emotional23.8 ± 36.742.8 ± 46.5
Mental Health8.6 ± 17.214.4 ± 25.8
SecondaryChange From Baseline in the Euro Quality of Life 5D

Change from baseline in Euro Quality of Life-5D from 3 Year Follow-Up to 5 to 7 Year Follow-Up Baseline Visit 1 (ITT Set) Euro Quality of Life 5D (EQ-5D): is a descriptive system of healthrelated quality of life states consisting of five dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) each of which can be assessed as one of three levels of severity (no problems/some or moderate problems/extreme problems). A Visual Analogue Scale (VAS)-scale is also included in the EQ-5D questionnaire. The EQ-5D index is calculated based on the United Kingdom Time Trade-Off (TTO) N3 value set which converts the five dimensions scores into a single measure with a possible range from -0.163 (worst possible health state) to +1 (perfect health). A positive change from baseline indicates an improvement in Quality of Life.

Time frame:
Baseline, 5-7 year visit
Reported as:
Mean · scores on the scale
Change From Baseline in the Euro Quality of Life 5D
scores on the scaleEverolimusControl
Change From Baseline in the Euro Quality of Life 5D0.2323 ± 0.38490.2982 ± 0.3274
SecondaryChange From Baseline in Visual Analog Scale (VAS)

Change in visual analog scale (VAS) from baseline to the 5 to 7 Year follow up visit. 0 is no pain; and 10 is the worst possible pain

Time frame:
baseline, at the 5-7 year visit
Reported as:
Mean · mm
Change From Baseline in Visual Analog Scale (VAS)
mmEverolimusControl
Change From Baseline in Visual Analog Scale (VAS)35.6 ± 26.934.0 ± 32.0
SecondaryNumber of Participants With Beck Depression Inventory (BDI)

Beck Depression Inventory (BDI) Score has the following categories of depression. Normal, Mild, Moderate Severe and Missing.

Time frame:
at the 5-7 year visit
Reported as:
Count of participants · Participants
Number of Participants With Beck Depression Inventory (BDI)
ParticipantsEverolimusControl
Normal1513
Mild64
Moderate25
Severe10
Missing35

Adverse events

Collected over An average of 3 years (from the 3 year follow-up visit to the 5-7 year follow-up visit). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Everolimus0/48 (0%)26/48 (54.2%)15/48 (31.3%)
Control0/47 (0%)18/47 (38.3%)4/47 (8.5%)
Most frequent serious events
Showing 10 of 45
Most frequent serious events
EventEverolimusControl
PneumoniaRespiratory, thoracic and mediastinal disorders13/483/47
PneumoniaInfections and infestations13/483/47
DiarrhoeaGastrointestinal disorders0/482/47
Upper respiratory tract infectionInfections and infestations2/482/47
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/482/47
Cardiac failureCardiac disorders2/480/47
DiverticulitisInfections and infestations2/480/47
SepsisInfections and infestations2/480/47
SyncopeNervous system disorders2/480/47
DepressionPsychiatric disorders2/480/47
Most frequent other events
Most frequent other events
EventEverolimusControl
PneumoniaInfections and infestations8/482/47
Oedema peripheralGeneral disorders5/480/47
DiarrhoeaGastrointestinal disorders4/483/47
SepsisInfections and infestations3/480/47

Baseline characteristics

The Intention-to-Treat Set (ITT Set) consists of patients who: * were included in the ITT in the Clinical Study Reports Addendum dated 11 August 2015 for the 3 year Follow-up visit * had at least one assessment of the efficacy variables mGFR or cGFR at the 5 to 7 year Follow-up

Age, Continuous
Age, Continuous(Years)EverolimusControlTotal
Mean50.13 ± 13.4352.11 ± 11.6151.11 ± 12.53
Sex: Female, Male
Sex: Female, Male(Participants)EverolimusControlTotal
Female131225
Male353570
Race (NIH/OMB)
Race (NIH/OMB)(Participants)EverolimusControlTotal
American Indian or Alaska Native000
Asian123
Native Hawaiian or Other Pacific Islander000
Black or African American011
White474491
More than one race000
Unknown or Not Reported000
08

Study locations

6 sites
  • Novartis Investigative Site
    Copenhagen, DK-2100, Denmark
  • Novartis Investigative Site
    Århus N, DK-8200, Denmark
  • Novartis Investigative Site
    Oslo, 0372, Norway
  • Novartis Investigative Site
    Göteborg, 413 45, Sweden
  • Novartis Investigative Site
    Linkoping, 581 85, Sweden
  • Novartis Investigative Site
    Lund, 221 85, Sweden
09

References and documents

Publications

  • Andreassen AK, Andersson B, Gustafsson F, Eiskjaer H, Radegran G, Gude E, Jansson K, Solbu D, Karason K, Arora S, Dellgren G, Gullestad L; SCHEDULE investigators. Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Three-Year Results From the Randomized SCHEDULE Study. Am J Transplant. 2016 Apr;16(4):1238-47. doi: 10.1111/ajt.13588. Epub 2016 Jan 28. PubMed 26820618 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2016 to primary completion in Sep 2017, 20 months.

Results were first posted in Oct 2019, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2016
First posted
Aug 12, 2016
StartActual
Jan 18, 2016
Primary completionActual
Sep 25, 2017
CompletionActual
Sep 25, 2017
Results first posted
Oct 3, 2019
Last update
Oct 3, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 3, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02864706
Responsible party
Sponsor
First posted
Aug 12, 2016
Start date
Jan 18, 2016
Primary completion
Sep 25, 2017
Completion
Sep 25, 2017
Results posted
Oct 3, 2019
Last update
Oct 3, 2019

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Everolimus

Start the discussion